Group 1 - The fourth meeting of the board of directors of Shenzhen Weiguang Biological Products Co., Ltd. was held on November 11, 2025, with all 9 directors present [2][4] - The board approved the appointment of Liu Xuefen as the new secretary of the board, effective immediately until the end of the current board's term [3][34] - The board also approved the reappointment of Da Xin Accounting Firm as the auditor for the fiscal year 2025, with a total fee of 760,000 yuan (excluding travel expenses) [5][45] Group 2 - A temporary shareholders' meeting is scheduled for November 27, 2025, to discuss the approved proposals from the board meeting [8][9] - The meeting will be held both in-person and via online voting, with specific time slots for each [15][16] - Shareholders must register by November 21, 2025, to participate in the meeting [17][19] Group 3 - The company announced the resignation of Jin Jianjun as the board secretary, who will continue as the marketing director [34] - Liu Xuefen, the newly appointed board secretary, has a strong background in corporate governance and has previously held senior positions in other companies [34][36] - The company emphasizes that Liu does not have any conflicts of interest with other board members or major shareholders [36] Group 4 - Da Xin Accounting Firm has a workforce of 3,945, including 1,031 certified public accountants, and has provided services to over 10,000 companies [38][39] - The firm reported a revenue of 1.575 billion yuan in 2024, with 1.378 billion yuan coming from audit services [39] - The company has a solid track record with no criminal penalties in the last three years, although it has faced some administrative penalties [41][43]

Core Viewpoint - The company announced a delay in the completion date of its expansion and technological transformation project from September 2025 to June 2026, while ensuring that the project’s implementation subject, fundraising purpose, and investment scale remain unchanged [13][28]. Company Overview - The company is South Qiao Food Group (Shanghai) Co., Ltd., with the stock code 605339 [4]. - The company’s board of directors and all members guarantee the truthfulness, accuracy, and completeness of the announcement content [4][12]. Financial Data - The company raised a total of RMB 1,078,729,415.76 through its initial public offering, with a net amount of RMB 991,277,271.83 after deducting issuance costs [14][38]. - As of June 30, 2025, the company had a balance of RMB 381,340,115.11 in its fundraising account [39][42]. Important Matters - The company’s board approved the delay of the expansion and technological transformation project, which is crucial for meeting market demand and enhancing production efficiency [18][28]. - The delay is attributed to the need for dynamic adjustments in production line and equipment selection to align with market changes [19][28]. Project Changes - The company has changed the implementation subject of certain fundraising projects, with the cold dough production line now being managed by Guangzhou South Qiao Food Co., Ltd. instead of Tianjin South Qiao Food Co., Ltd. [15]. - The company has also reduced the fundraising amount for specific projects by a total of RMB 205.35 million [15][16]. Project Implementation Necessity and Feasibility - The expansion and technological transformation project is deemed necessary to optimize product structure and adapt to the growing baking market [18][20]. - The company possesses a complete production system and extensive management experience, which supports the feasibility of the project [20][21]. Expected Benefits - The project is expected to enhance production efficiency and product competitiveness, aligning with industry trends towards technological innovation and sustainable practices [19][20][28]. Measures for Fund Usage - The company plans to strengthen internal audits and external supervision of fundraising usage to ensure compliance and efficiency [24]. - The company will closely monitor market changes and report on project progress regularly [24][28]. Recent Performance - In July 2025, the company reported a consolidated revenue of RMB 198.10 million, a decrease of 9.19% year-on-year [69].